Humacyte, Inc. short interest in 2024
In 2024, Humacyte, Inc.'s disclosed short interest ran from 5.92% of shares outstanding on 12 Jan 2024 to 23.53% on 31 Dec 2024, a change of +17.61 percentage points. The year's high was 23.53% on 31 Dec 2024 and its low 3.31% on 15 Apr 2024, averaging 9.34% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 17.65 days on 12 Jan 2024. Full history: Humacyte, Inc..
Cite this page
By year: 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 5.92% (12 Jan 2024)
- End of year
- 23.53% (31 Dec 2024)
- Change
- +17.61 pp
- High
- 23.53% (31 Dec 2024)
- Low
- 3.31% (15 Apr 2024)
- Average
- 9.34%
- Highest days to cover
- 17.65 (12 Jan 2024)
- SEC filings marked
- 8
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 5.92% | 17.65 | |
| 31 Jan 2024 | 5.92% | 15.50 | |
| 15 Feb 2024 | 6.33% | 6.60 | |
| 29 Feb 2024 | 5.75% | 6.91 | |
| 15 Mar 2024 | 3.65% | 2.14 | |
| 28 Mar 2024 | 3.35% | 3.41 | results (8-K), 10-K filed |
| 15 Apr 2024 | 3.31% | 3.66 | |
| 30 Apr 2024 | 3.77% | 2.16 | |
| 15 May 2024 | 3.52% | 1.94 | results (8-K), 10-Q filed |
| 31 May 2024 | 4.13% | 1.33 | |
| 14 Jun 2024 | 4.37% | 2.49 | |
| 28 Jun 2024 | 6.93% | 2.14 | |
| 15 Jul 2024 | 12.26% | 3.32 | |
| 31 Jul 2024 | 10.08% | 3.58 | |
| 15 Aug 2024 | 9.56% | 2.94 | 10-Q filed, results (8-K) |
| 30 Aug 2024 | 9.45% | 5.02 | |
| 13 Sep 2024 | 11.74% | 5.89 | |
| 30 Sep 2024 | 13.43% | 6.44 | |
| 15 Oct 2024 | 13.97% | 5.86 | |
| 31 Oct 2024 | 14.45% | 4.74 | |
| 15 Nov 2024 | 15.21% | 5.43 | 10-Q filed, results (8-K) |
| 29 Nov 2024 | 16.16% | 6.89 | |
| 13 Dec 2024 | 17.45% | 9.10 | |
| 31 Dec 2024 | 23.53% | 2.40 |
See also: Humacyte, Inc.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.